While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.